[Treatment of rheumatoid spondylarthritis with salazosulfapyridine]

Abstract

Salazosulfapyridine (salazopyrin) (SASP) is effective basic treatment for rheumatoid arthritis (RA) after failure or intolerance of antimalarials or gold salts. Sulfapyridine is the active part of the molecule. Its mechanism of action probably involves anti-inflammatory activity as well as effects on cells participating in immune reactions. Adverse reactions occur in approximately one third of cases, in the majority of instances during the first three months of treatments. Simple digestive upsets are the commonest, but SASP may be responsible for sometimes severe cutaneous, hematological and hepatic reactions. The sometimes delayed onset of intolerance reactions justifies continuous monitoring of laboratory parameters. Results obtained with SASP are sometimes prolonged and therapeutic maintenance rates are similar to those seen with other basic treatment for RA. The use of SASP in RA should be tried before methotrexate in relatively early forms of the disease.